CERRITOS, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) have announced their executives’ participation in multiple panel presentations at the upcoming APG 2024 Spring Conference in San Diego. Chief Medical Officer, Dr. Yale Podnos, will be discussing artificial intelligence and its uses in an oncology practice in the breakout session panel “AI on the Front Lines: Improving Outcomes and Reducing Costs for Complex Patients”. Dr. Daniel Virnich, Chief Executive Officer, will join other industry leaders on another panel, “Assuming Global Risk for Pharmaceuticals.”
About The Oncology Institute
Founded in 2007, The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 110+ employed clinicians and over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Investors at Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.31 |
Daily Change: | -0.005 -1.59 |
Daily Volume: | 219,389 |
Market Cap: | US$23.400M |
September 30, 2024 August 13, 2024 May 14, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB